NF-κB p105/p50 Mouse monoclonal Antibody IgM
Fig1: Western blot analysis of NF-κB p105/p50 on MCF-7 cell lysates.
Fig2: Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using anti-NF-κB p105/p50 antibody. Counter stained with hematoxylin.
Fig3: ICC staining NF-κB p105/p50 in HepG2 cells (red). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Host Species; Species ReactivityMouse; Human, Mouse
ImmunogenThis antibody is produced by immunizing mice with a synthetic Peptide (KLH-coupled) corresponding to NF-κB p105/p50.
Application SummaryWB, ICC, IHC
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesNuclear factor NF-kappa-B p105 subunit,DNA-binding factor KBF1,EBP-1,Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
BackgroundNF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators.(M1505-8)